Hematologic Malignancy
Lymphoid Neoplasm
CI-CAN-00009335Explore in graph →
Hematologic2,419 active trials60 approved drugs271 evidence items
- OncoTree
- LNM
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00009335Explore in graph →
Clinical trials
8,886 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,374)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00002787 | Vaccine Therapy in Treating Patients With Multiple Myeloma Who Have Undergone Stem Cell Transplantation | completed | Phase 1 | 22 | Fred Hutchinson Cancer Research Center/University of Washington Cancer ConsortiumOTHER | 1 | May 6, 2019 | clinicaltrials |
| NCT00863174 | A Bioequivalence Study of SPARC_147709 in Patients With Multiple Myeloma | completed | Phase 1 | 24 | Sun Pharma Advanced Research Company LimitedINDUSTRY | 0 | May 3, 2019 |
| clinicaltrials |
| NCT02243436 | Brentuximab Vedotin in Pre-transplant Induction and Consolidation for Relapsed or Refractory Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 67 | Grupo Español de Linfomas y Transplante Autólogo de Médula ÓseaOTHER | 1 | Apr 24, 2019 | clinicaltrials |
| NCT01246063 | Carfilzomib, Pegylated Liposomal Doxorubicin Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 40 | Washington University School of MedicineOTHER | 1 | Apr 8, 2019 | clinicaltrials |
| NCT01521611 | Targeted Radiotherapy in HSCT for Poor Risk Haematological Malignancy | completed | Phase 1 / Phase 2 | 62 | University Hospital Southampton NHS Foundation TrustOTHER | 1 | Apr 8, 2019 | clinicaltrials |
| NCT00586924 | A Phase I, Multicenter Dose Escalation Study in Patients With Hairy Cell Leukemia | completed | Phase 1 | 49 | MedImmune LLCINDUSTRY | 2 | Apr 2, 2019 | clinicaltrials |
| NCT00802113 | Autologous and Allogeneic Transplant for Relapsed Lymphoma | completed | Phase 1 / Phase 2 | 30 | Columbia UniversityOTHER | 1 | Mar 27, 2019 | clinicaltrials |
| NCT01383928 | Study of Oral IXAZOMIB in Combination With Lenalidomide and Dexamethasone in Participants With Newly Diagnosed Multiple Myeloma | completed | Phase 1 / Phase 2 | 64 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Mar 21, 2019 | clinicaltrials |
| NCT01556438 | Study of Tabalumab (LY2127399) in Japanese Participants With Relapsed or Refactory Multiple Myeloma | completed | Phase 1 | 16 | Eli Lilly and CompanyINDUSTRY | 1 | Mar 20, 2019 | clinicaltrials |
| NCT02497378 | A Study of JNJ-54767414 (Daratumumab) in Combination With Bortezomib and Dexamethasone (D-Vd) in Japanese Participants With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 | 8 | Janssen Pharmaceutical K.K.INDUSTRY | 1 | Mar 7, 2019 | clinicaltrials |
| NCT00520130 | Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System | completed | Phase 1 / Phase 2 | 92 | National Cancer Institute (NCI)NIH | 1 | Mar 5, 2019 | clinicaltrials |
| NCT02745769 | A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents | completed | Phase 1 | 23 | Eli Lilly and CompanyINDUSTRY | 3 | Mar 5, 2019 | clinicaltrials |
| NCT01440582 | Combination Therapy of Lenalidomide/Bortezomib/Dexamethasone and Panobinostat in Transplant Eligible New Diagnosed Multiple Myeloma (MM) Patients | completed | Phase 1 | 77 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 4, 2019 | clinicaltrials |
| NCT02549651 | MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Relapsed/Refractory DLBCL (D4190C00023) | completed | Phase 1 | 32 | MedImmune LLCINDUSTRY | 4 | Feb 27, 2019 | clinicaltrials |
| NCT01874054 | Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 55 | Seagen Inc.INDUSTRY | 1 | Feb 12, 2019 | clinicaltrials |
| NCT00943319 | Busulfan-fludarabine Conditioning and T-cell Depleted Allogeneic Stem Cell Transplantation for Patients With Advanced Hematologic Malignancies | completed | Phase 1 / Phase 2 | 50 | University of ChicagoOTHER | 1 | Feb 4, 2019 | clinicaltrials |
| NCT01897012 | Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas | completed | Phase 1 | 26 | National Cancer Institute (NCI)NIH | 1 | Jan 28, 2019 | clinicaltrials |
| NCT01634217 | Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplantation | completed | Phase 1 | 16 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Jan 18, 2019 | clinicaltrials |
| NCT02976857 | A Phase 1 Study Evaluating Safety and Efficacy of C-CAR011 Treatment in DLBCL Subjects(C-CAR011) | completed | Phase 1 | 15 | Shanghai AbelZeta Ltd.INDUSTRY | 1 | Jan 17, 2019 | clinicaltrials |
| NCT01549431 | Study of the Combination of Panobinostat & Carfilzomib in Patients With Relapsed &/or Refractory Multiple Myeloma | completed | Phase 1 | 32 | Emory UniversityOTHER | 1 | Jan 16, 2019 | clinicaltrials |
| NCT00076180 | Hu-Mik-beta1 to Treat T-Cell Large Granular Lymphocytic Leukemia | completed | Phase 1 | 9 | National Cancer Institute (NCI)NIH | 1 | Jan 11, 2019 | clinicaltrials |
| NCT02240719 | Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer | completed | Phase 1 | 20 | University of California, DavisOTHER | 1 | Jan 4, 2019 | clinicaltrials |
| NCT00923520 | A Phase 1, Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous Dimethane Sulfonate (DMS612) in Advanced Malignancies | completed | Phase 1 | 60 | National Cancer Institute (NCI)NIH | 1 | Dec 5, 2018 | clinicaltrials |
| NCT01165112 | Bendamustine Hydrochloride, Rituximab, Etoposide, and Carboplatin in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma or Hodgkin Lymphoma(TREC) | completed | Phase 1 / Phase 2 | 48 | University of WashingtonOTHER | 1 | Dec 5, 2018 | clinicaltrials |
| NCT01401530 | E7777 for the Treatment of Patients With Peripheral T-Cell Lymphoma | completed | Phase 1 | 13 | Eisai Co., Ltd.INDUSTRY | 1 | Nov 23, 2018 | clinicaltrials |
| NCT01306643 | Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymphoma | completed | Phase 1 / Phase 2 | 18 | Gilead SciencesINDUSTRY | 1 | Nov 19, 2018 | clinicaltrials |
| NCT01645930 | Phase 1 Pharmacokinetic Study of Oral Ixazomib Plus Lenalidomide and Dexamethasone in Adult Asian Participants With Relapsed and/or Refractory Multiple Myeloma | completed | Phase 1 | 43 | Millennium Pharmaceuticals, Inc.INDUSTRY | 3 | Nov 8, 2018 | clinicaltrials |
| NCT01342289 | Shorter Course Tacrolimus After Nonmyeloablative, Related Donor BMT With High-dose Posttransplantation Cyclophosphamide | completed | Phase 1 | 127 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Oct 17, 2018 | clinicaltrials |
| NCT00231166 | Safety, Efficacy, Dose-finding Study of a Monoclonal Antibody in Patients With Multiple Myeloma | completed | Phase 1 | 33 | Novartis PharmaceuticalsINDUSTRY | 2 | Oct 11, 2018 | clinicaltrials |
| NCT00024466 | Chemotherapy, Vaccine Therapy, and Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma | completed | Phase 1 / Phase 2 | 28 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Sep 19, 2018 | clinicaltrials |
| NCT01590732 | Romidepsin, Ifosfamide, Carboplatin, and Etoposide in Treating Participants With Relapsed or Refractory Peripheral T-Cell Lymphoma | completed | Phase 1 | 22 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 19, 2018 | clinicaltrials |
| NCT01355705 | Phase 1-2 Amrubicin in Combo With Lenalidomide + Weekly Dexamethasone in Relapsed/Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 14 | Michaela LiedtkeOTHER | 1 | Sep 18, 2018 | clinicaltrials |
| NCT03107663 | ⁸⁹Zr-Df-IAB22M2C PET/CT in Patients With Selected Solid Malignancies or Hodgkin's Lymphoma | completed | Phase 1 | 15 | ImaginAb, Inc.INDUSTRY | 1 | Sep 18, 2018 | clinicaltrials |
| NCT01950273 | Pharmacokinetics and Pharmacodynamics of BI 695500 vs. Rituximab as First Line-treatment in Patients With Low Tumor Burden Follicular Lymphoma | completed | Phase 1 | 95 | Boehringer IngelheimINDUSTRY | 13 | Sep 5, 2018 | clinicaltrials |
| NCT01272466 | Vaccination With Peptides From Anti-apoptotic Proteins in Relapsed Multiple Myeloma | completed | Phase 1 / Phase 2 | 40 | Herlev HospitalOTHER | 1 | Aug 31, 2018 | clinicaltrials |
| NCT01707264 | Phase 1/2, Open Label, Dose Escalation Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis | completed | Phase 1 / Phase 2 | 69 | Prothena Biosciences Ltd.INDUSTRY | 1 | Aug 28, 2018 | clinicaltrials |
| NCT00779584 | A Dose-escalation Study of MK-8776 (SCH 900776) With and Without Gemcitabine in Participants With Solid Tumors or Lymphoma (MK-8776-002/P05248) | completed | Phase 1 | 45 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 27, 2018 | clinicaltrials |
| NCT00901615 | Lenalidomide and R-CHOP in B-cell Lymphoma(R2CHOP-1) | completed | Phase 1 / Phase 2 | 108 | Lymphoma Study AssociationOTHER | 1 | Aug 23, 2018 | clinicaltrials |
| NCT00777114 | Phase 1 Study of Radiosensitization Using Bortezomib in Relapsed Non-Hodgkin's Lymphoma Patients Receiving Radioimmunotherapy | completed | Phase 1 | 31 | Weill Medical College of Cornell UniversityOTHER | 1 | Aug 13, 2018 | clinicaltrials |
| NCT00701103 | Dose Escalation Trial of Dalotuzumab (MK-0646) in Advanced Solid Tumors and Multiple Myeloma (MK-0646-001) | completed | Phase 1 | 80 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 8, 2018 | clinicaltrials |
| NCT01428492 | Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma(PKB115125) | completed | Phase 1 | 90 | NovartisINDUSTRY | 5 | Aug 8, 2018 | clinicaltrials |
| NCT01690143 | Carfilzomib + High Dose Melphalan as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation | completed | Phase 1 / Phase 2 | 45 | University of Alabama at BirminghamOTHER | 1 | Aug 7, 2018 | clinicaltrials |
| NCT00484874 | Safety and Efficacy Study of I-131 Tositumomab in Patients With Relapsed/Refractory Hodgkin's Lymphoma | completed | Phase 1 / Phase 2 | 12 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Aug 1, 2018 | clinicaltrials |
| NCT01777243 | A Study to Evaluate the Safety of GSK2398852 When Co-administered With GSK2315698 in Patients With Systemic Amyloidosis | completed | Phase 1 | 25 | GlaxoSmithKlineINDUSTRY | 1 | Jul 24, 2018 | clinicaltrials |
| NCT01484015 | Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia | completed | Phase 1 | 70 | Wake Forest University Health SciencesOTHER | 1 | Jul 18, 2018 | clinicaltrials |
| NCT02071888 | Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors | completed | Phase 1 | 25 | Calithera Biosciences, IncINDUSTRY | 1 | Jul 18, 2018 | clinicaltrials |
| NCT00001830 | Donor Th2 Cells to Prevent Graft-Versus-Host Disease in Bone Marrow Transplants | completed | Phase 1 | 110 | National Cancer Institute (NCI)NIH | 1 | Jul 5, 2018 | clinicaltrials |
| NCT01563302 | Phase 1/2, Open-label, Dose-escalation Study of IONIS-STAT3Rx, Administered to Patients With Advanced Cancers | completed | Phase 1 / Phase 2 | 64 | Ionis Pharmaceuticals, Inc.INDUSTRY | 1 | Jun 25, 2018 | clinicaltrials |
| NCT00151320 | Phase I/II Trial of VELCADE + CHOP-Rituximab in Untreated DLCBL or Mantle Cell NHL | completed | Phase 1 / Phase 2 | 76 | Weill Medical College of Cornell UniversityOTHER | 1 | Jun 19, 2018 | clinicaltrials |
| NCT01129193 | AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma | completed | Phase 1 | 44 | Amir MortazaviOTHER | 1 | Jun 4, 2018 | clinicaltrials |
Data updated 23 days agoSource updated May 6, 2019source: clinicaltrials